Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear
Patient Selection and Monitoring Best Practices 503A pharmacy protocols should screen candidates for personal/family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2, as these contraindicate both agents regardless of perceived safety advantages
A randomized controlled trial is a type of study where participants are randomly assigned to different treatments, which provides stronger scientific evidence
Swelling of face, lips, tongue, or throat
Your KLOW protocol is prepared by our 503A compounding pharmacy partner and shipped to the clinic or directly to your door
C., Hou, J., Mora, F., Harms, A
